ClinicalTrials.gg
Not yet recruitingNCT07946601Updated Nov 18, 2026

Genomic ctDNA-Informed De-escalation And Neoadjuvant Chemotherapy Omission in Cystectomy

A Phase 2 interventional study of ctDNA testing in Muscle Invasive Bladder Cancer (MIBC), sponsored by Case Comprehensive Cancer Center. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Case Comprehensive Cancer Center · Phase 2, Interventional, and Supportive care

Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 883 studies in Urinary Bladder Neoplasms with a site in United States — 163 open to participants now, 269 under way, 31 of them phase 3. Urinary Bladder Neoplasms · United States.

Planned enrollment
157th of 715
150 · median 46
Started
2027
with 5 others
Phase 2
238 of 883
33 open now
Primary completion
2029-01
later than 216 of 266 live
Registered
883rd of 883
by date

Among the 883 studies in Urinary Bladder Neoplasms with a site in United States, this one is the 157th largest by planned enrollment of the 715 interventional ones that give a count, is one of 6 that started in 2027, is one of 238 in phase 2, reaches primary completion later than 216 of the 266 other live ones, and was the 883rd registered.

Urinary Bladder Neoplasms

1,801 studies on the registry are indexed under Urinary Bladder Neoplasms; 446 are open to participants now.

Browse Urinary Bladder Neoplasms studies →

Open to participants now

163 of the 883 studies in Urinary Bladder Neoplasms with a site in United States are open now. Recruiting first, the newest first:

158 more — sign in →

All 163 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 337 Urinary Bladder Neoplasms studies recruiting now, 257 (76%) set no upper age limit and 22 (7%) stop at 75 or younger; 22 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 883 studies in Urinary Bladder Neoplasms with a site in United States, or all of them as a file.
02

Study summary

This study is for participants who have recently been diagnosed with muscle-invasive bladder cancer (MIBC) who are eligible for the surgical removal of the entire bladder, and have undergone ctDNA testing with a negative result. The purpose of this study is to investigate the outcomes for ctDNA negative MIBC participants who do not receive neoadjuvant chemotherapy before undergoing bladder removal.

Read the detailed description

Muscle-invasive bladder cancer is an aggressive form of cancer with a high chance of metastasis at the time of diagnosis. The standard of care treatment for MIBC is neoadjuvant chemotherapy (NAC), followed by radical cystectomy or removal of the entire bladder, and then pelvic lymph node dissection. While NAC improves the overall survival at 5 years, it is associated with significant toxicities and there are many patient who do not benefit from it. Because of this, there is a need for predictive biomarkers to identify participants who can directly go into surgery without undergoing NAC. Recent studies have shown circulating tumor DNA (ctDNA) to be highly sensitive and specific predictive biomarker, and ctDNA negative participants have excellent outcomes and that skipping NAC is not harmful for these participants. The aim of this study is find out the safety and efficacy of omitting NAC in participants with MIBC who are ctDNA negative before their planned radical cystectomy. By using personalized ctDNA biomarkers, this will help spare patients the toxicity and delay unnecessary chemotherapy while still maintaining excellent outcomes.

03

Conditions studied

  • Muscle Invasive Bladder Cancer (MIBC)

Keywords

  • MIBC
  • muscle invasive bladder cancer
  • cTDNA-Infomrmed De-escalation
  • Neoadjuvant Chemotherapy Omission
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed muscle-invasive urothelial carcinoma of the bladder (cT2- T4aN0M0).
  • Planned for radical cystectomy with curative intent.
  • Negative for ctDNA using a validated, tumor-informed assay (Natera Signatera) from a blood sample collected prior to any systemic therapy. Must have 2 negative tests within the screening window.
  • Age ≥ 18 years.
  • (ECOG) Performance Status of 0, 1, or 2.
  • Adequate organ function as defined by standard laboratory criteria.
  • Ability to understand and provide written .

Exclusion criteria

Exclusion Criteria:

  • Evidence of clinical node-positive or disease (cN+ or cM1) on baseline imaging.
  • Prior systemic therapy (chemotherapy or immunotherapy) for urothelial carcinoma within the past 12 months.
  • Positive ctDNA status at baseline (defined as a positive result on either of the two pre-operative Natera Signatera tests).
  • Variant histology comprising >50% of the tumor volume (e.g., small cell, sarcomatoid, plasmacytoid).
  • Uncontrolled concurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, or psychiatric illness that would limit compliance with study requirements.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Supportive care
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    ctDNA-negative MIBC

    There will be a pilot lead-in phase for the first 30 participants who are eligible due to the risks associated. Participants who are newly diagnosed with MIBC who are candidates for radical cystectomy will undergo baseline ctDNA test. Participants who are confirmed to be ctDNA negative will be enrolled in the study and will proceed directly to radical cystectomy without neoadjuvant chemotherapy (NAC). After surgery, participants will undergo standard of care assessments.

    Diagnostic Test: ctDNA testing

Interventions

  • Diagnostic testctDNA testing

    Newly diagnosed MIBC participants who are candidates for radical cystectomy will first undergo baseline ctDNA testing to see if they are ctDNA negative. If the participant is confirmed ctDNA negative, they will be enrolled in the study and undergo radical cystectomy without neoadjuvant chemotherapy.

06

What researchers measure

Primary outcomes

  1. Recurrence free survival (RFS)

    RFS is defined as the time from the date of cystectomy in ctDNA-negative MIBC participants to the date of first documented radiological recurrence per RECIST v1.1 or death, whichever occurs first.

    Time frame: 2 years

Secondary outcomes

  1. Overall survival (OS)

    Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

    Time frame: at 2 years

  2. Overall survival

    Overall survival is defined as the duration of time from the start of treatment to time of death from any cause.

    Time frame: at 5 years

  3. Rate of pathological complete response (pCR)

    To assess the rate of pathological complete response and pathological tumor characteristics at the time cystectomy.

    Time frame: at day 0

  4. Rates of surgical morbidity

    To evaluate surgical morbidity in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

    Time frame: up to 4 weeks

  5. Rates of complications

    To evaluate complications in participants undergoing only cystectomy compared to participants receiving neoadjuvant therapy.

    Time frame: up to 4 weeks

  6. Positive predictive value

    To evaluate the positive predictive value of baseline ctDNA status for pathological lymph node involvement

    Time frame: days -42 to 0

  7. Negative predictive value

    To evaluate the negative predictive value of baseline ctDNA status for pathological lymph node involvement

    Time frame: days -42 to 0

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — There is not currently an intention or plan to share IPD

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Jan 2029, 24 months later.

Of 154 non-industry phase 2 interventional studies under Urinary Bladder Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 94. This study's planned 24 months is below that.

Counting every sponsor, half of 193 studies reached it within 52 months; a quarter within 36 and three quarters within 91.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 12, 2026
First posted
Nov 18, 2026
StartEst.
Jan 2027
Primary completionEst.
Jan 2029
CompletionEst.
Dec 2032
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07946601
Collaborators
Natera, Inc.
Responsible party
Sponsor
First posted
Nov 18, 2026
Start date
Jan 2027 (estimated)
Primary completion
Jan 2029 (estimated)
Completion
Dec 2032 (estimated)
Last update
Nov 18, 2026

Study contacts

Laura Bukavina, MD, MPH, MSc
Contact
bukavil2@ccf.org
(216) 444-6043
Myra Krnac
Contact
krnacm@ccf.org
(216)444-1047
Laura Bukavina, MD, MPH, MSc
principal investigator · The Cleveland Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion